Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases

No abstract is available for this paper.

• Publication year

  2011

• Venue

  British Journal of Surgery

• Publication date

  2011-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/bjs.7368PMID 21254017
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983)

  2016cited by this paper
• Implication des hépato-gastroentérologues en cancérologie digestive ? Enquête de la Fédération des spécialités des maladies de l’appareil digestif (FSMAD) et la Fédération francophone de cancérologie digestive (FFCD)

  2012cited by this paper
• Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin‐associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis

  2010cited by this paper
• Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.

  2009cited by this paper
• Prediction of Postoperative Outcome After Hepatectomy With a New Bedside Test for Maximal Liver Function Capacity

  2009cited by this paper
• Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab

  2009cited by this paper
• Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

  2008cited by this paper
• Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

  2008cited by this paper
• Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?

  2008cited by this paper
• Sinusoidal Injury Increases Morbidity After Major Hepatectomy in Patients With Colorectal Liver Metastases Receiving Preoperative Chemotherapy

  2008cited by this paper
• Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

  2008cited by this paper
• Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.

  2008cited by this paper
• Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.

  2008cited by this paper
• Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer: A Multifactorial Model of 929 Patients

  2008cited by this paper
• Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases

  2008cited by this paper
• Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

  2007cited by this paper
• Bringing unresectable liver disease to resection with curative intent.

  2007cited by this paper
• Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases

  2007cited by this paper
• Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

  2007cited by this paper
• Randomised controlled trial

  2006cited by this paper
• Feasibility of metastasectomy in patients treated with bevacizumab in first-line mCRC - Preliminary results from the First Beat-study.

  2006cited by this paper
• Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.

  2006cited by this paper
• Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab.

  2005cited by this paper
• Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.

  2005cited by this paper
• Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.

  2005cited by this paper
• Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

  2005cited by this paper
• The “50-50 Criteria” on Postoperative Day 5: An Accurate Predictor of Liver Failure and Death After Hepatectomy

  2005cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey

  2004cited by this paper
• Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival

  2004cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.

  1999cited by this paper
• Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.

  1999cited by this paper

• Synthetic tumor extracellular volume as a predictive biomarker for colorectal liver metastasis patients prior to curative hepatectomy

  2025cites this paper
• Preoperative Versus Postoperative Chemotherapy With CAPOX Plus Bevacizumab for Resectable Colorectal Liver Metastases: A Randomized Phase II Trial (HiSCO‐01)

  2025cites this paper
• Overview of the Surgical Management of Liver Oligometastatic Disease in Colorectal Cancer

  2025cites this paper
• From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies

  2023cites this paper
• Mortality of patients with metastatic colorectal cancer who received elective or emergent operation after exposure to bevacizumab: A nationwide database study.

  2022cites this paper
• Evaluation of histopathological heterogeneity of colorectal cancer liver metastasis sites after preoperative chemotherapy

  2022cites this paper
• Evaluation of Histopathological Heterogeneity After Preoperative Chemotherapy in Patients With Liver Metastases from Colorectal Cancer

  2021cites this paper
• Drug induced liver injury and vascular liver disease.

  2020cites this paper
• Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review.

  2019cites this paper
• Colorectalis májmetastasisok komplex kezelése. Konszenzuskonferencia, Budapest, 2019. április 5.

  2019cites this paper
• Clinicopathological characteristics associated with necrosis in pulmonary metastases from colorectal cancer

  2019cites this paper
• Bevacizumab Allows Preservation Of Liver Function and its Regenerative Capacity After Major Hepatectomy.

  2019cites this paper
• RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer

  2018cites this paper
• A Population-Based Study of Complications After Colorectal Surgery in Patients Who Have Received Bevacizumab

  2018cites this paper
• Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.

  2018cites this paper
• Neoadjuvant chemotherapy does not affect future liver remnant growth and outcomes of associating liver partition and portal vein ligation for staged hepatectomy

  2017cites this paper
• Equivalent cross-relaxation rate imaging and diffusion weighted imaging for early prediction of response to bevacizumab-containing treatment in colorectal liver metastases-preliminary study.

  2017cites this paper
• 11 Neoadjuvant Chemotherapy for Colorectal Liver Metastases

  2017influential citation
• Conversion and Neoadjuvant Therapies

  2017cites this paper
• Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

  2016cites this paper
• Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab

  2016cites this paper
• Use of Bevacizumab in the Management of Potentially Resectable Colorectal Liver Metastases: Safety, Pathologic Assessment and Benefit

  2016cites this paper
• Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases

  2016influential citation
• Regenerative liver surgeries: the alphabet soup of emerging techniques

  2016cites this paper
• Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.

  2015cites this paper
• Bevacizumab and postoperative wound complications in patients with liver metastases of colorectal cancer.

  2015cites this paper
• Progress of transformational therapy in colorectal liver metastases

  2015cites this paper
• A 5-year recurrence-free survivor with over ten colorectal liver metastases undergoing FOLFOX plus bevacizumab followed by two-stage hepatectomy

  2015cites this paper
• Liver-directed therapies in metastatic colorectal cancer.

  2014cites this paper
• Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).

  2014cites this paper
• Correlación radio-patológica de criterios morfológicos en la valoración de metástasis hepáticas de adenocarcinoma de colon

  2014cites this paper
• Pathological Complete Response after Systemic Chemotherapy for an Ascending Colon Cancer with Unresectable Multiple Liver Metastases

  2014cites this paper
• Addition of bevacizumab to preoperative chemotherapy for colorectal liver metastases does not increase perioperative morbidity and mortality.

  2014cites this paper
• Chemotherapy-associated liver injury and its influence on outcome after resection of colorectal liver metastases.

  2014influential citation
• Floxuridine Hepatic Arterial Infusion Associated Biliary Toxicity Is Increased by Concurrent Administration of Systemic Bevacizumab

  2014cites this paper
• [Surgical treatment of metastases and its impact on prognosis in patients with metastatic colorectal carcinoma].

  2014cites this paper
• Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

  2013influential citation
• Bevacizumab Treatment Before Resection of Colorectal Liver Metastases: Safety, Recovery of Liver Function, Pathologic Assesment

  2013influential citation
• Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'

  2013cites this paper
• Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

  2013influential citation
• Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases.

  2013cites this paper
• Evaluating necrosis and chemotherapy response in colorectal cancer liver metastases. Comment on Knijn et al. (2013)

  2013cites this paper
• Systemic treatment of liver metastases from colorectal cancer

  2013cites this paper
• Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement.

  2013cites this paper
• Defining resectability of colorectal liver metastases: how and why?

  2013cites this paper
• What is the optimal neo-adjuvant treatment for liver metastasis?

  2013cites this paper
• Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'

  2013cites this paper
• Resectable liver metastases from colorectal cancer: where we are now and where do we go from here?

  2012cites this paper
• Volumetric Analysis of Remnant Liver Regeneration After Major Hepatectomy in Bevacizumab-Treated Patients: A Case-Matched Study in 82 Patients

  2012cites this paper
• Immediately preoperative use of biological therapy does not influence liver regeneration after large resection--porcine experimental model with monoclonal antibody against epidermal growth factor.

  2012cites this paper
• Surgical Results after Downstaging of Initially Marginal or Non-Resectable Liver Metastases

  2012cites this paper
• Tumor and non-tumor liver angiogenesis is traced and evaluated by hepatic arterial ultrasound in murine models.

  2012cites this paper
• Safety of hepatic resection for colorectal metastases in the era of neo-adjuvant chemotherapy

  2012cites this paper
• Infarct-like Necrosis: A Distinct Form of Necrosis Seen in Colorectal Carcinoma Liver Metastases Treated With Perioperative Chemotherapy

  2012cites this paper
• Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?

  2012cites this paper
• Neoadjuvant Chemotherapy for Colorectal Liver Metastases

  2012influential citation
• Preoperative use of Biological Therapy Does not Influence Liver Regeneration after Large Resection-Porcine Experimental Model with Monoclonal Antibody against Epidermal Growth Factor

  2012cites this paper
• Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases--a systematic review.

  2012cites this paper
• Neoadjuvant chemotherapy for non-/resectable metastases.

  2011cites this paper
• Neoadjuvante Therapiekonzepte bei Lebermetastasen

  2011cites this paper
• [Management of colorectal liver metastases after induction treatment. The pathologist's role in 2011].

  2011cites this paper
• MIT Open Access

  year unknowncites this paper